GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars
2023-06-29| Partnerships

Vertex and Lonza Collaborate to Revolutionize Type 1 Diabetes Treatment

by GeneOnline
Share To

Vertex Pharmaceuticals Incorporated and Lonza have partnered to revolutionize the treatment of type 1 diabetes (T1D). Their collaboration focuses on stem cell-derived islet cell therapies, particularly the VX-880 and VX-264 programs in clinical trials. Vertex is making remarkable progress in the fight against T1D.

In a recent breakthrough, Vertex’s VX-880 program demonstrated clinical proof-of-concept, showing promising results. All six patients treated with VX-880 not only received islet cells but also produced their own insulin (C-peptide) while improving glycemic control. This achievement offers hope for millions living with T1D and paves the way for further treatment advancements.

Related article: Should Weight Loss Seekers Skip Sugar Substitutes?

Manufacturing Collaboration: Vertex and Lonza Working Together

To speed up development and commercialization of their therapies, Vertex and Lonza have formed a strategic partnership. Leveraging Lonza’s expertise in cell and gene technologies and operational excellence, Vertex aims to scale up manufacturing and expand patient access.

The collaboration includes establishing a dedicated facility in Portsmouth, New Hampshire, operated by Lonza. This advanced facility, spanning over 130,000 square feet, is expected to create up to 300 jobs at its peak, demonstrating the commitment of both companies to advancing T1D treatment.

Vertex and Lonza Shaping the Future of Care for Type 1 Diabetes

The partnership between Vertex and Lonza marks a significant milestone in transforming T1D treatment. Vertex’s innovation combined with Lonza’s manufacturing capabilities sets the stage for groundbreaking advancements in the lives of T1D patients worldwide.

With their joint efforts, Vertex and Lonza are determined to push the boundaries of T1D care. Through scientific innovation, manufacturing expertise, and a shared dedication to patients, they chart a new path toward improved outcomes and a brighter future for individuals with T1D.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Roche Secures CE Mark for AI-Powered Glucose Monitoring Solution, Enhancing Diabetes Care with Predictive Insights
2024-07-11
M&A
Vertex Pharmaceuticals Makes $4.9 Billion Bet on Kidney Disease Treatment through Alpine Immune Acquisition
2024-04-11
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
Scroll to Top